Videos

Nathan A. Pennell, MD, PhD, discusses the importance of developing new RET inhibitors for patients with non–small cell lung cancer.

Centering discussion around the combination of lenvatinib + pembrolizumab in advanced clear cell RCC, Hans Hammers, MD, considers the role of this combination regimen in the first-line treatment setting.

Expert hematologist/oncologist Brian Rini, MD, spearheads a comprehensive discussion on the broad treatment landscape for advanced clear cell renal cell carcinoma.

Adam Cohen, MD, discusses the current FDA-approved BCMA-directed therapies in the multiple myeloma space and the clinical data supporting each agent.

Krzysztof J. Misiukiewicz, MD, discusses when targeted therapy may be used for patients with NTRK-positive thyroid cancer.

Rachel Wuerstein, MD, discusses the KAMILLA trial of trastuzumab emtansine in metastatic breast cancer for both a global and Asian cohort.

David S. Hong, MD, discusses what he sees for the future of the NTRK inhibitor larotrectinib.

Adam Weiner, MD, discusses the results of his research on molecular subtyping in prostate cancer.

Wojciech Jurczak, MD, PhD, discusses the available treatment options for patients with relapsed/refractory chronic lymphocytic leukemia who relapsed on BCL2 inhibitors.

Scott Tykodi, MD, PhD, reviews data from the CLEAR trial investigating 2 IO combination therapies for advanced renal cell carcinoma treatment.

Drs Tannir, Tykodi, and Ornstein debate whether single-agent TKI therapies still have a place in advanced clear cell RCC treatment, especially for favorable-risk patients.

Edward E. Garon, MS, MS, discusses results from the phase 3 CANOPY-A study of adjuvant canakinumab for the treatment of patients with completely resected non-small cell lung cancer.

Paul A. DiSilvestro discusses the 7-year follow-up results from the phase 3 SOLO1/GOG-3004 trial.

Ruben Mesa, MD, discusses crucial data from the COMFORT studies that show ruxolitinib's benefit in patients with myelofibrosis.

Steven M. Albelda, MD, discusses what he expects the future of chimeric antigen receptor T-cell use in solid tumors to look like.

Ronald S. Go, MD, discusses what community oncologists should know regarding the guidelines on managing patients with histiocytic neoplasms.

Erminia Massarelli, MD, PhD, MS, discusses the efficacy outcomes of the CHRYSALIS trial of amivantamab in patients with non–small cell lung cancer and an EGFR exon 20 insertion.

Moshe Ornstein, MD, MA, explains the factors he considers when deciding on a combination treatment regimen for a patient with favorable-risk advanced clear cell RCC.

An expert presents the case of a 68-year-old woman with favorable-risk advanced clear cell RCC for discussion.

David Barrington, MD, discusses the next steps for oncologists treating patients with stage 1B, grade 3 endometrial cancer.

Erika P. Hamilton, MD, discusses the background of a phase 1 trial of DS-6000a in patients with advanced renal cell carcinoma and ovarian cancer.

Daneng Li, MD, discusses potential second-line options following treatment with bevacizumab plus atezolizumab in patients with hepatocellular carcinoma.

Valencia D. Thomas, MD, MHCM, discusses the unmet needs which remain in the non-melanoma skin cancer space.

Sumanta K. Pal, MD, discusses the safety and efficacy results of the COSMIC-021 clinical trial.

Giuseppe Fallaro, MD, discusses research comparing baseline characteristics of patients with renal cell carcinoma treated with adjuvant pembrolizumab in the real-world setting compared with those treatment treated in the KEYNOTE-564.

Srdan Verstovsek, MD, PhD, discusses why the first ever FDA approved interferon drug ropeginterferon alfa-2b-njft is important for adult patients with polycythemia vera.

Nicolas Gazeau, MS, discusses next steps and unmet needs following a positive retrospective study of anakinra for the management of neurotoxicity and cytokine release syndrome in patients who received chimeric antigen receptor T-cell therapy.

Karen L. Reckamp, MD, discusses the key findings of the phase 2 Lung-MAP substudy S1800A for patients with stage IV, previously-treated non–small cell lung cancer.

Dr. Marc Matrana closes the discussion with considerations for clinicians on treating patients with prostate cancer.

Insight on recent developments and emerging options in the mCSPC treatment landscape.